Emerging Perspectives on mTOR Inhibitor-Associated Pneumonitis in Breast Cancer

The Oncologist
Ricardo H AlvarezJames M Reuben

Abstract

Substantial improvements in the early detection and treatment of breast cancer have led to improvements in survival, but breast cancer remains a significant cause of morbidity and mortality in women. In 2012, the mammalian target of rapamycin (mTOR) inhibitor everolimus was approved by the U.S. Food and Drug Administration for the treatment of advanced breast cancer in patients resistant to endocrine therapy. Although everolimus is generally well tolerated, mTOR inhibitor-associated pneumonitis is one of the most common adverse drug events leading to treatment discontinuation. To date, the underlying pathophysiology of this toxicity is unclear, and this uncertainty may hinder the optimization of management strategies. However, experiences from breast cancer and renal cell carcinoma clinical trials indicate that mTOR inhibitor-associated pneumonitis can be effectively managed by early detection, accurate diagnosis, and prompt intervention that generally involves everolimus dose reductions, interruptions, or discontinuation. Management can be achieved by a multidisciplinary approach that involves the collaborative efforts of nurses, oncologists, radiologists, infectious disease specialists, pulmonologists, clinical pharmacists, a...Continue Reading

References

Feb 1, 1994·The American Journal of Surgical Pathology·A L Katzenstein, R F Fiorelli
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Michael B AtkinsMatthew L Sherman
Apr 29, 2004·Transplantation·Phuong-Thu T PhamAlan H Wilkinson
Aug 18, 2004·Genes & Development·Nissim Hay, Nahum Sonenberg
Jul 22, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anne BoulayHeidi A Lane
Feb 14, 2006·Cell·Stephan WullschlegerMichael N Hall
Jun 30, 2006·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·I DuranM Niroumand
Aug 19, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M BeeramL A DeGraffenried
Oct 14, 2008·Immunity·Thomas WeichhartMarcus D Säemann
Apr 22, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·José BaselgaHope S Rugo
Apr 22, 2009·Targeted Oncology·Kamalesh SankhalaMonica Mita
Jun 25, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J-C SoriaV Papadimitrakopoulou
Aug 1, 2009·Nature Reviews. Drug Discovery·Pixu LiuJean J Zhao
Aug 8, 2009·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Guadalupe AparicioLuis M Antón Aparicio
Aug 19, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Susan L EllardLesley Seymour
Jan 21, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Kevin D CourtneyJeffrey A Engelman
Mar 3, 2010·American Journal of Respiratory and Critical Care Medicine·Dorothy A WhiteRobert J Motzer
Oct 6, 2010·Cancer Metastasis Reviews·Carlos A CastanedaEva M Ciruelos
Oct 27, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fabrice AndreSara A Hurvitz
Feb 11, 2011·The New England Journal of Medicine·James C YaoUNKNOWN RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group
Mar 30, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jose Pablo MarotoAnna Berkenblit
Apr 13, 2011·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Camillo PortaRobert J Motzer
Dec 14, 2011·The New England Journal of Medicine·José BaselgaGabriel N Hortobagyi
Mar 28, 2012·The Journal of Immunology : Official Journal of the American Association of Immunologists·Jill A FielhaberArnold S Kristof
Apr 10, 2012·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Donnette A DabydeenToni K Choueiri
Apr 12, 2012·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Yuanxi ZhuJin Zhang
Jun 13, 2012·Annals of Oncology : Official Journal of the European Society for Medical Oncology·L AlbigesP Camus
Jul 4, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hope S Rugo, Sara Keck
Sep 25, 2012·Nature·UNKNOWN Cancer Genome Atlas Network
Dec 13, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonio C WolffDaniel F Hayes
Sep 10, 2013·Cancer Treatment Reviews·Parvin F PeddiSara A Hurvitz
Sep 17, 2013·American Journal of Respiratory and Critical Care Medicine·William D TravisUNKNOWN ATS/ERS Committee on Idiopathic Interstitial Pneumonias
Mar 13, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·H S RugoH A Burris
Mar 29, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·M AaproA Ravaud
May 6, 2014·American Journal of Physiology. Lung Cellular and Molecular Physiology·Satoshi WashinoTatsuo Morita
Aug 15, 2014·The Oncologist·Francesco PanzutoGianfranco Delle Fave

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.